

Silvia C Formenti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6332820/publications.pdf>

Version: 2024-02-01

163
papers

24,544
citations

19636

61
h-index

9334

143
g-index

171
all docs

171
docs citations

171
times ranked

22279
citing authors

#	ARTICLE	IF	CITATIONS
1	Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. <i>Science</i> , 2015, 350, 1079-1084.	6.0	2,539
2	Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody. <i>Clinical Cancer Research</i> , 2009, 15, 5379-5388.	3.2	1,371
3	DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. <i>Nature Communications</i> , 2017, 8, 15618.	5.8	1,194
4	Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 862-870.	0.4	1,166
5	Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. <i>Lancet Oncology</i> , The, 2017, 18, 895-903.	5.1	872
6	Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift. <i>Journal of the National Cancer Institute</i> , 2013, 105, 256-265.	3.0	846
7	Using immunotherapy to boost the abscopal effect. <i>Nature Reviews Cancer</i> , 2018, 18, 313-322.	12.8	844
8	Systemic effects of local radiotherapy. <i>Lancet Oncology</i> , The, 2009, 10, 718-726.	5.1	822
9	Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. <i>Clinical Cancer Research</i> , 2005, 11, 728-34.	3.2	662
10	<i>Enterococcus hirae</i> and <i>Barnesiella intestinihominis</i> Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. <i>Immunity</i> , 2016, 45, 931-943.	6.6	645
11	Radiotherapy induces responses of lung cancer to CTLA-4 blockade. <i>Nature Medicine</i> , 2018, 24, 1845-1851.	15.2	626
12	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
13	Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells. <i>Journal of Immunology</i> , 2008, 181, 3099-3107.	0.4	604
14	An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2013, 1, 365-372.	1.6	599
15	Role of Local Radiation Therapy in Cancer Immunotherapy. <i>JAMA Oncology</i> , 2015, 1, 1325.	3.4	570
16	Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. <i>Lancet Oncology</i> , The, 2015, 16, 795-803.	5.1	546
17	Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. <i>Oncotarget</i> , 2014, 3, e28518.	2.1	439
18	TGF- β 2 Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. <i>Cancer Research</i> , 2015, 75, 2232-2242.	0.4	429

#	ARTICLE	IF	CITATIONS
19	Combining radiotherapy and immunotherapy: A revived partnership. International Journal of Radiation Oncology Biology Physics, 2005, 63, 655-666.	0.4	320
20	Current clinical trials testing the combination of immunotherapy with radiotherapy. , 2016, 4, 51.		317
21	Radiotherapy: Changing the Game in Immunotherapy. Trends in Cancer, 2016, 2, 286-294.	3.8	270
22	Radiation as an immunological adjuvant: current evidence on dose and fractionation. Frontiers in Oncology, 2012, 2, 153.	1.3	259
23	Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs. Cancer Immunology Research, 2018, 6, 910-920.	1.6	245
24	Radiation Therapy to Convert the Tumor Into an In Situ Vaccine. International Journal of Radiation Oncology Biology Physics, 2012, 84, 879-880.	0.4	244
25	Prone accelerated partial breast irradiation after breast-conserving surgery: Preliminary clinical results and doseâ€volume histogram analysis. International Journal of Radiation Oncology Biology Physics, 2004, 60, 493-504.	0.4	225
26	TGFÎ²1 Inhibition Increases the Radiosensitivity of Breast Cancer Cells<i>In Vitro</i>and Promotes Tumor Control by Radiation<i>In Vivo</i>. Clinical Cancer Research, 2011, 17, 6754-6765.	3.2	217
27	Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Nature Immunology, 2020, 21, 1160-1171.	7.0	214
28	Combinations of Immunotherapy and Radiation in Cancer Therapy. Frontiers in Oncology, 2014, 4, 325.	1.3	205
29	Focal Irradiation and Systemic TGFÎ²2 Blockade in Metastatic Breast Cancer. Clinical Cancer Research, 2018, 24, 2493-2504.	3.2	201
30	The Integration of Radiotherapy with Immunotherapy for the Treatment of Nonâ€Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 5792-5806.	3.2	200
31	Cytosolic DNA Sensing in Organismal Tumor Control. Cancer Cell, 2018, 34, 361-378.	7.7	191
32	Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncology, The, 2021, 22, 824-835.	5.1	191
33	Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer. Clinical Cancer Research, 2012, 18, 6748-6757.	3.2	183
34	Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. Genome Medicine, 2019, 11, 40.	3.6	179
35	Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells. Cancer Immunology Research, 2018, 6, 139-150.	1.6	172
36	Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation. Clinical Cancer Research, 2010, 16, 681-690.	3.2	167

#	ARTICLE	IF	CITATIONS
37	Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. Journal of Clinical Investigation, 2012, 122, 3718-3730.	3.9	167
38	Phase I-II Trial of Prone Accelerated Intensity Modulated Radiation Therapy to the Breast to Optimally Spare Normal Tissue. Journal of Clinical Oncology, 2007, 25, 2236-2242.	0.8	154
39	The Combination of Ionizing Radiation and Peripheral Vaccination Produces Long-term Survival of Mice Bearing Established Invasive GL261 Gliomas. Clinical Cancer Research, 2006, 12, 4730-4737.	3.2	151
40	Barriers to Radiation-Induced In Situ Tumor Vaccination. Frontiers in Immunology, 2017, 8, 229.	2.2	149
41	In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine, 2015, 33, 7415-7422.	1.7	142
42	Synergy of Topical Toll-like Receptor 7 Agonist with Radiation and Low-Dose Cyclophosphamide in a Mouse Model of Cutaneous Breast Cancer. Clinical Cancer Research, 2012, 18, 6668-6678.	3.2	140
43	Prone vs Supine Positioning for Breast Cancer Radiotherapy. JAMA - Journal of the American Medical Association, 2012, 308, 861.	3.8	138
44	Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers. Clinical Cancer Research, 2018, 24, 259-265.	3.2	137
45	Current Clinical Trials Testing Combinations of Immunotherapy and Radiation. Seminars in Radiation Oncology, 2015, 25, 54-64.	1.0	123
46	Prospective Assessment of Optimal Individual Position (Prone Versus Supine) for Breast Radiotherapy: Volumetric and Dosimetric Correlations in 100 Patients. International Journal of Radiation Oncology Biology Physics, 2012, 84, 902-909.	0.4	120
47	Preoperative Twice-Weekly Paclitaxel With Concurrent Radiation Therapy Followed by Surgery and Postoperative Doxorubicin-Based Chemotherapy in Locally Advanced Breast Cancer: A Phase I/II Trial. Journal of Clinical Oncology, 2003, 21, 864-870.	0.8	118
48	Myeloid-Derived Cells in Tumors: Effects of Radiation. Seminars in Radiation Oncology, 2015, 25, 18-27.	1.0	116
49	Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. Pathogens and Immunity, 2021, 6, 116-134.	1.4	112
50	Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. Journal of Clinical Investigation, 2021, 131, .	3.9	111
51	T1 Stage Breast Cancer: Adjuvant Hypofractionated Conformal Radiation Therapy to Tumor Bed in Selected Postmenopausal Breast Cancer Patientsâ€”Pilot Feasibility Study. Radiology, 2002, 222, 171-178.	3.6	109
52	Sensors of ionizing radiation effects on the immunological microenvironment of cancer. International Journal of Radiation Biology, 2007, 83, 819-825.	1.0	109
53	Radiation-Induced Chromosomal Aberrations and Immunotherapy: Micronuclei, Cytosolic DNA, and Interferon-Production Pathway. Frontiers in Oncology, 2018, 8, 192.	1.3	96
54	Invariant Natural Killer T Cells Regulate Breast Cancer Response to Radiation and CTLA-4 Blockade. Clinical Cancer Research, 2009, 15, 597-606.	3.2	87

#	ARTICLE	IF	CITATIONS
55	Radiotherapy and checkpoint inhibitors: a winning new combination?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876824.	1.4	87
56	CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection. Cancer Immunology Research, 2020, 8, 465-478.	1.6	87
57	Immunomodulation by anticancer cell cycle inhibitors. Nature Reviews Immunology, 2020, 20, 669-679.	10.6	86
58	TREX1 dictates the immune fate of irradiated cancer cells. OncoImmunology, 2017, 6, e1339857.	2.1	81
59	Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. Nature Reviews Clinical Oncology, 2022, 19, 114-131.	12.5	76
60	Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Research and Treatment, 2010, 124, 723-732.	1.1	75
61	The abscopal effect 67 years later: from a side story to center stage. British Journal of Radiology, 2020, 93, 20200042.	1.0	73
62	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nature Communications, 2020, 11, 3819.	5.8	71
63	Cancer and COVID-19 – potentially deleterious effects of delaying radiotherapy. Nature Reviews Clinical Oncology, 2020, 17, 332-334.	12.5	68
64	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. , 2016, 4, 15.		67
65	Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology, 2017, 6, e1373237.	2.1	62
66	External-beam partial-breast irradiation. Seminars in Radiation Oncology, 2005, 15, 92-99.	1.0	60
67	Does Heavy Ion Therapy Work Through the Immune System?. International Journal of Radiation Oncology Biology Physics, 2016, 96, 934-936.	0.4	60
68	Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality. International Journal of Radiation Biology, 2019, 95, 936-939.	1.0	57
69	Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking?. , 2016, 4, 29.		54
70	Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities. International Journal of Radiation Oncology Biology Physics, 2021, 110, 35-52.	0.4	54
71	Harnessing radiation to improve immunotherapy: better with particles?. British Journal of Radiology, 2020, 93, 20190224.	1.0	53
72	Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-Fluorouracil and radiation therapy. International Journal of Radiation Oncology Biology Physics, 1997, 39, 1059-1068.	0.4	51

#	ARTICLE	IF	CITATIONS
73	Local control by radiotherapy: is that all there is?. Breast Cancer Research, 2008, 10, 215.	2.2	51
74	PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. Gynecologic Oncology, 2020, 159, 322-328.	0.6	51
75	Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy. Clinical Breast Cancer, 2016, 16, 113-122.e1.	1.1	49
76	Predicting Biochemical Disease-Free Survival after Prostate Stereotactic Body Radiotherapy: Risk-Stratification and Patterns of Failure. Frontiers in Oncology, 2016, 6, 168.	1.3	48
77	Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation. Advances in Radiation Oncology, 2018, 3, 486-493.	0.6	48
78	Accelerated Intensity-Modulated Radiotherapy to Breast in Prone Position: Dosimetric Results. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1251-1259.	0.4	47
79	Radiation Therapy and the In Situ Vaccination Approach. International Journal of Radiation Oncology Biology Physics, 2020, 108, 891-898.	0.4	46
80	Is tumor (R)ejection by the immune system the 5th R of radiobiology?. Oncoimmunology, 2014, 3, e28133.	2.1	45
81	First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. Clinical Cancer Research, 2020, 26, 1025-1033.	3.2	45
82	Prone Breast Intensity Modulated Radiation Therapy: 5-Year Results. International Journal of Radiation Oncology Biology Physics, 2014, 89, 899-906.	0.4	41
83	Risk and Risk Reduction of Major Coronary Events Associated With Contemporary Breast Radiotherapy. JAMA Internal Medicine, 2014, 174, 158.	2.6	41
84	Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer. Clinical Cancer Research, 2021, 27, 1855-1863.	3.2	41
85	Prone Hypofractionated Whole-Breast Radiotherapy Without a Boost to the Tumor Bed: Comparable Toxicity of IMRT Versus a 3D Conformal Technique. International Journal of Radiation Oncology Biology Physics, 2012, 82, e415-e423.	0.4	40
86	Activin A Promotes Regulatory T-cell-Mediated Immunosuppression in Irradiated Breast Cancer. Cancer Immunology Research, 2021, 9, 89-102.	1.6	39
87	Integration of radiation and immunotherapy in breast cancer - Treatment implications. Breast, 2018, 38, 66-74.	0.9	38
88	Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?. Radiation Research, 2020, 194, 452-464.	0.7	36
89	Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. International Journal of Radiation Oncology Biology Physics, 2002, 52, 397-405.	0.4	35
90	Effects of Chemoradiation on Tumor-Host Interactions: The Immunologic Side. Journal of Clinical Oncology, 2008, 26, 1562-1563.	0.8	35

#	ARTICLE	IF	CITATIONS
91	Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade. <i>Oncolmunology</i> , 2020, 9, 1830524.	2.1	34
92	Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients. , 2019, 7, 177.		32
93	The Impact of Radiation Therapy on Innate and Adaptive Tumor Immunity. <i>Seminars in Radiation Oncology</i> , 2020, 30, 139-144.	1.0	32
94	Radiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses. <i>Cancer Immunology Research</i> , 2020, 8, 1054-1063.	1.6	31
95	The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer. <i>Oncolmunology</i> , 2013, 2, e25997.	2.1	30
96	Radiation-induced Adaptive Response: New Potential for Cancer Treatment. <i>Clinical Cancer Research</i> , 2020, 26, 5781-5790.	3.2	30
97	3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine. <i>Nature Communications</i> , 2021, 12, 4447.	5.8	30
98	Radiation Therapy and Immunotherapy: Growing Pains. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 252-254.	0.4	29
99	Qualitative Assessment of Academic Radiation Oncology Department Chairs' Insights on Diversity, Equity, and Inclusion: Progress, Challenges, and Future Aspirations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 30-45.	0.4	29
100	Dual Transforming Growth Factor- β 2 and Programmed Death-1 Blockade: A Strategy for Immune-Excluded Tumors?. <i>Trends in Immunology</i> , 2018, 39, 435-437.	2.9	27
101	Current Status and Recommendations for the Future of Research, Teaching, and Testing in the Biological Sciences of Radiation Oncology: Report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, Executive Summary. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 11-17.	0.4	26
102	Burnout in United States Academic Chairs of Radiation Oncology Programs. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 363-368.	0.4	25
103	Estimating child mortality associated with maternal mortality from breast and cervical cancer. <i>Cancer</i> , 2019, 125, 109-117.	2.0	22
104	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. <i>Breast</i> , 2022, 63, 123-139.	0.9	22
105	Future of Radiation and Immunotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 3-5.	0.4	21
106	Enhancing Career Paths for Tomorrow's Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 52-63.	0.4	20
107	Global Breast Cancer: The Lessons to Bring Home. <i>International Journal of Breast Cancer</i> , 2012, 2012, 1-7.	0.6	19
108	Prospective Randomized Trial of Prone Accelerated Intensity Modulated Breast Radiation Therapy With a Daily Versus Weekly Boost to the Tumor Bed. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 571-578.	0.4	19

#	ARTICLE	IF	CITATIONS
109	Locally Advanced Breast Cancer “ Strategies for Developing Nations. <i>Frontiers in Oncology</i> , 2015, 5, 89.	1.3	18
110	PTEN at the interface of immune tolerance and tumor suppression. <i>Frontiers in Biology</i> , 2017, 12, 163-174.	0.7	18
111	Rapid, robust, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals. <i>JCI Insight</i> , 2021, 6, .	2.3	18
112	SPECIAL DEPARTMENTS. <i>Journal of Clinical Oncology</i> , 2000, 18, 1159-1159.	0.8	16
113	Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Oncologist</i> , 2021, 26, e1508-e1513.	1.9	16
114	Cesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes. <i>Journal of Contemporary Brachytherapy</i> , 2015, 6, 445-452.	0.4	14
115	PTEN as a Guardian of the Genome: Pathways and Targets. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036194.	2.9	14
116	Radiosurgery and Immunotherapy in the Treatment of Brain Metastases. <i>World Neurosurgery</i> , 2019, 130, 615-622.	0.7	13
117	Development of a Model to Estimate the Association Between Delay in Cancer Treatment and Local Tumor Control and Risk of Metastases. <i>JAMA Network Open</i> , 2021, 4, e2034065.	2.8	13
118	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	1.8	12
119	Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial. , 2019, 7, 318.		12
120	Hypofractionated Whole-Breast Irradiation in Women Less Than 50 Years Old Treated on 4 Prospective Protocols. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1159-1167.	0.4	11
121	Pro-oncogenic cytokines and growth factors are differentially expressed in the post-surgical wound fluid from malignant compared to benign breast lesions. <i>SpringerPlus</i> , 2015, 4, 483.	1.2	10
122	Results of a phase “II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer. <i>Oncotarget</i> , 2017, 6, e1274479.	2.1	10
123	Preplanning prediction of the left anterior descending artery maximum dose based on patient, dosimetric, and treatment planning parameters. <i>Advances in Radiation Oncology</i> , 2016, 1, 373-381.	0.6	9
124	Understanding Responses to Stereotactic Body Radiotherapy and Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2018, 36, 2661-2662.	0.8	9
125	Shaping the Path for a Global Oncology Academic Career. <i>JAMA Oncology</i> , 2019, 5, 931.	3.4	9
126	Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC. <i>Lancet Oncology</i> , The, 2022, 23, e156.	5.1	9

#	ARTICLE	IF	CITATIONS
127	Clinical Trial Evidence of the Antitumor Activity of Topical Imiquimod for Breast Cancer Skin Metastases. <i>Journal of Clinical Oncology</i> , 2014, 32, 3204-3205.	0.8	8
128	Raising the Next Generation of Physician-Scientists: The Chairs' Perspective. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 211-213.	0.4	8
129	External-beam-based partial breast irradiation. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 326-327.	4.3	7
130	Unique changes in the TCR repertoire of tumor-infiltrating lymphocytes underlie the synergy of radiotherapy with CTLA-4 blockade. , 2014, 2, .		6
131	Mobile mammography in New York City: analysis of 32,350 women utilizing a screening mammogram program. <i>Npj Breast Cancer</i> , 2022, 8, 14.	2.3	6
132	Quality of Life in Women Undergoing Breast Irradiation in a Randomized, Controlled Clinical Trial Evaluating Different Tumor Bed Boost Fractionations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 579-589.	0.4	5
133	Is classical stereotactic radiotherapy the optimal partner for immunotherapy?. <i>Oncology</i> , 2015, 29, 340, 347, 387.	0.4	5
134	Introduction. <i>Seminars in Radiation Oncology</i> , 2015, 25, 1-3.	1.0	4
135	Radiotherapy for extensive stage small-cell lung cancer. <i>Lancet, The</i> , 2015, 385, 1290-1291.	6.3	3
136	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th,) Tj ETQq0 0 0,rgBT /Over	1.8	3
137	Natural history of lower urinary tract symptoms among men undergoing stereotactic body radiation therapy for prostate cancer with and without a Rectal Hydrogel Spacer. <i>World Journal of Urology</i> , 2022, 40, 1143-1150.	1.2	3
138	Positioning During Radiotherapy for Breast Cancer"Reply. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 137.	3.8	2
139	The Pace of Progress in Radiation and Immunotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1257-1258.	0.4	2
140	Subverting misconceptions about radiation therapy. <i>Nature Immunology</i> , 2016, 17, 345-345.	7.0	2
141	Treatment of Non-Melanomatous Skin Cancer with Radiotherapy. <i>Current Dermatology Reports</i> , 2015, 4, 187-194.	1.1	1
142	Local radiotherapy and GM-CSF in metastatic cancer: lessons from a proof of principle trial. <i>OncolImmunology</i> , 0, , 00-00.	2.1	1
143	Combining Radiotherapy and Immunotherapy. <i>Cancer Treatment and Research</i> , 2017, , 1-20.	0.2	1
144	Introduction to the special edition on immunotherapy and radiation oncology. <i>Advances in Radiation Oncology</i> , 2018, 3, 484-485.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Radiation Therapy in Gabon: Multi-Institutional Collaboration as a Paradigm for Growth in the African Radiation Oncology Sector. International Journal of Radiation Oncology Biology Physics, 2020, 106, 663-668.	0.4	1
146	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2ndâ€“3rd,) Tj ETQq0 0.0 rgBT /Overlock 1	1.8	1
147	Therapeutic effect of local Interleukin-15 with radiotherapy in breast cancer.. Journal of Clinical Oncology, 2017, 35, 158-158.	0.8	1
148	More radiotherapy for radiation-induced second malignancies?. Breast Cancer Research and Treatment, 2010, 124, 851-852.	1.1	0
149	Society of Chairs of Academic Radiation Oncology Programsâ€“Endorsed Radiation Oncology Department Review Process. International Journal of Radiation Oncology Biology Physics, 2015, 92, 536-539.	0.4	0
150	Perspectives in immunotherapy: meeting report from the â€œImmunotherapy Bridgeâ€“, Napoli, December 5th 2015. , 2016, 4, .		0
151	Synergy Between Radiotherapy and Immunotherapy. , 2018, , 507-524.		0
152	Analysis of Pathologic Complete Response 10 Weeks After Radiotherapyâ€”A Radiobiological Sin. JAMA Oncology, 2019, 5, 1365.	3.4	0
153	Abstract IA003: Radiotherapy effects on tumor microenvironment. , 2021, , .		0
154	Abstract PO-036: Immunological characterization of mouse HR+ mammary tumors relapsing after radiation therapy. , 2021, , .		0
155	Liver Metastasis Irradiation Can Restore Immunotherapeutic Responsiveness. Trends in Immunology, 2021, 42, 275-277.	2.9	0
156	Abstract IA-014: Strategies to enhance the immunogenicity of radiation therapy. , 2021, , .		0
157	Abstract PO-070: Boost tumor response to radiation therapy: What can we learn from PTEN-deficient models?. , 2021, , .		0
158	Impact of maternal death from female cancers on child mortality.. Journal of Clinical Oncology, 2015, 33, 6591-6591.	0.8	0
159	Preoperative radiotherapy for high-risk prostate cancer (PORT-PC) trial.. Journal of Clinical Oncology, 2019, 37, TPS137-TPS137.	0.8	0
160	Synergy of Immunotherapy and Radiosurgery. , 2020, , 355-369.		0
161	733â€œ...Immunological mechanisms of resistance to CDK4/CDK6 inhibitors in breast cancer. , 2021, 9, A763-A763.		0
162	285â€œ...Breaking through the resistance of breast cancer to immune checkpoint blockers in a unique mouse model of HR+ disease. , 2021, 9, A309-A309.		0

#	ARTICLE	IF	CITATIONS
163	822â€¦Local radiotherapy synergizes with tumor-specific TCR redirected T cells in the rejection of prostate cancer. , 2020, , .		0